Stress Urinary Incontinence and Platelet-Rich Plasma Therapy: A Survey

www.surveyx.cn

Abstract

This survey paper provides a comprehensive examination of stress urinary incontinence (SUI), a prevalent condition characterized by involuntary urine leakage during activities that increase abdominal pressure, and explores the potential of platelet-rich plasma (PRP) therapy as a treatment. The paper systematically reviews the prevalence, risk factors, and impact of SUI, highlighting limitations of current treatments such as surgical interventions and pharmacological options. It delves into the definitions and core concepts of SUI and PRP, elucidating the biological mechanisms underpinning PRP therapy, including growth factors and platelet activation. The survey evaluates existing clinical trials, identifying significant research gaps, particularly the lack of standardized PRP preparation protocols and large-scale randomized controlled trials. Challenges such as ethical considerations, regulatory frameworks, and variability in PRP formulations are addressed. Future directions emphasize the need for standardization, exploration of biological mechanisms, and integration with emerging technologies to optimize PRP's therapeutic potential. The paper concludes by underscoring PRP's promise as a minimally invasive treatment for SUI, advocating for continued research to establish its efficacy and safety, ultimately enhancing patient outcomes and expanding the therapeutic landscape.

1 Introduction

1.1 Structure of the Survey

This survey systematically explores stress urinary incontinence (SUI) and the application of platelet-rich plasma (PRP) therapy as a potential treatment. The **Introduction** discusses the significance of SUI and positions PRP therapy as a promising intervention. The subsequent **Background** section addresses the prevalence, causes, and impact of SUI, along with an overview of current standard treatments and their limitations.

The section titled **Definitions and Core Concepts** clarifies essential terminology and foundational principles related to SUI, PRP, regenerative medicine, and their interconnections within urology. Following this, the **Mechanism of Platelet-Rich Plasma Therapy** examines the biological underpinnings, including growth factors and biochemical pathways.

In **Clinical Trials and Evidence**, the survey reviews clinical trials evaluating the efficacy of PRP therapy for SUI, identifying gaps in the current research landscape. The **Challenges and Considerations** section addresses complexities associated with PRP therapy, including variability in preparation methods and ethical concerns.

The penultimate section, **Future Directions**, highlights areas for further research, emphasizing the necessity for standardized protocols, large-scale trials, and integration with emerging technologies. The concluding section synthesizes key findings and reiterates the potential of PRP therapy as a viable treatment for SUI, underscoring the importance of continued investigation in this promising field.The following sections are organized as shown in Figure 1.



Figure 1: chapter structure

2 Background

2.1 Prevalence and Epidemiology

Stress urinary incontinence (SUI) poses a significant public health challenge, notably affecting adult females, with a prevalence of 33.5% reported in Taiyuan [1]. Similar to other pelvic floor disorders like pelvic organ prolapse (POP), SUI incidence rises with age, often necessitating surgical intervention [2]. Understanding these epidemiological patterns is crucial for developing targeted interventions and optimizing healthcare resource allocation.

2.2 Risk Factors and Pathophysiology

SUI is a complex condition shaped by multiple anatomical and physiological factors, with its prevalence notably increasing in individuals over 40 due to the interaction between urethral pressure and age-related anatomical changes [3]. Key risk factors include childbirth, obesity, and menopause, which exacerbate these changes and complicate treatment [4]. In postmenopausal women, involuntary urine leakage during activities that elevate abdominal pressure, such as sneezing, highlights the need for targeted interventions [5].

The female urinary microbiota (FUM) significantly influences SUI's pathophysiology, though its treatment implications remain underexplored [6]. SUI involves intrinsic factors like urethral sphincter

AI-generated, for reference only.

incompetence and extrinsic factors such as pelvic floor muscle dysfunction [7]. Postpartum urinary incontinence exemplifies how these risk factors impact quality of life, underscoring the necessity for comprehensive management strategies [8].

Localized epidemiological data are vital for identifying specific risk factors within populations [1]. The variability in treatment responses, including to platelet-rich plasma (PRP) therapy, underscores the importance of personalized management approaches [9]. A thorough understanding of the interplay between risk factors and underlying mechanisms is essential for advancing preventive and therapeutic strategies for SUI.

2.3 Impact on Quality of Life

SUI substantially impairs quality of life, affecting physical and emotional well-being [1]. Despite available treatments, only 25% of affected women seek medical care, leading to underdiagnosis and undertreatment [10]. This underutilization exacerbates SUI's negative impact, causing social embarrassment, reduced physical activity, and diminished self-esteem [11]. The stigma associated with urinary incontinence further discourages symptom discussion, perpetuating neglect. Increased awareness and education are crucial to promote timely diagnosis and treatment, thereby mitigating SUI's adverse effects.

2.4 Current Standard Treatments

SUI management includes various treatment modalities, each with distinct challenges. Pelvic floor muscle training is a cornerstone of conservative management, enhancing urethral support through targeted exercises [11]. However, adherence is often hindered by accessibility and patient engagement issues [10]. Lifestyle modifications, such as weight management and dietary changes, are recommended to alleviate symptoms but may not address SUI's underlying complexities [12].

Pharmacological options exist but often yield inconsistent results due to the diverse etiological factors in SUI patients [10]. Surgical interventions, like mid-urethral slings and Burch colposuspension, offer more definitive solutions but carry risks of complications and variable success rates [13]. Concerns about surgical mesh, due to documented adverse events, necessitate careful patient selection and informed decision-making [14].

Current treatments' limitations are compounded by a lack of comprehensive understanding of bladder, urethra, and external pressure interactions, often leading to inadequate solutions for SUI [5]. Innovative treatments like PRP therapy remain exploratory, facing challenges related to variability in formulations and lack of standardized protocols [15]. The absence of large-scale randomized controlled trials to validate PRP's efficacy and safety in gynecological contexts underscores the need for rigorous research [16].

Moreover, heterogeneity in study designs, including selection bias and insufficient control for confounding variables like age and parity, complicates treatment efficacy evaluations [7]. Existing benchmarks primarily focus on women with occult SUI, leaving a knowledge gap regarding those who develop de novo SUI postoperatively [2]. Addressing these limitations requires a comprehensive approach that integrates both intrinsic and extrinsic factors influencing SUI, paving the way for more personalized and effective treatment strategies.

In recent years, the intersection of regenerative medicine and urology has garnered significant attention, particularly in the context of Stress Urinary Incontinence (SUI) and the therapeutic application of Platelet-Rich Plasma (PRP). Understanding the complex interplay of biological factors and clinical applications is essential for advancing treatment protocols. Figure 2 illustrates the hierarchical structure of core concepts related to SUI and PRP, providing a comprehensive overview of their definitions and pathophysiological factors. This figure categorizes the various elements impacting SUI, alongside the biological composition and therapeutic principles of PRP. Moreover, it underscores their integration into medical practice, highlighting the critical need for standardized protocols and the importance of ongoing research in this evolving field. This visual representation not only enhances our understanding but also serves as a pivotal reference point for further discussion on the implications of these findings in clinical settings.

AI-generated, for reference only.



Figure 2: This figure illustrates the hierarchical structure of core concepts related to Stress Urinary Incontinence (SUI) and Platelet-Rich Plasma (PRP), highlighting their definitions, pathophysiological factors, and roles in regenerative medicine and urology. It categorizes the factors affecting SUI, the biological composition and therapeutic principles of PRP, and their integration into medical practice, emphasizing the importance of standardized protocols and ongoing research.

3 Definitions and Core Concepts

3.1 Definition of Stress Urinary Incontinence

Stress urinary incontinence (SUI) is defined as involuntary urine leakage during activities that increase abdominal pressure, such as coughing, sneezing, or exercising [11]. Predominantly affecting women, SUI is often exacerbated by factors like childbirth, obesity, and menopause [4]. Its pathophysiology is complex, involving anatomical, physiological, and functional dimensions [7]. Anatomically, SUI is linked to the weakening of pelvic floor muscles and the urethral sphincter, crucial for continence [3]. Physiologically, variations in urethral pressure, influenced by age and measurement position, are significant [3]. Functionally, the interaction of bladder and urethra dynamics under external abdominal pressure provides mechanical insights [5].

This is further illustrated in Figure 3, which highlights the key aspects of stress urinary incontinence, including its definition and impact, pathophysiological mechanisms, and treatment approaches, drawing on various academic sources. SUI profoundly impacts quality of life, affecting individuals and their families [13]. Despite various treatment options, including mobile app-based interventions to enhance engagement and success rates [17], SUI remains a prevalent and challenging condition.



Figure 3: This figure illustrates the key aspects of stress urinary incontinence (SUI), including its definition and impact, pathophysiological mechanisms, and treatment approaches, drawing on various academic sources.

3.2 Definition and Principles of Platelet-Rich Plasma

Platelet-rich plasma (PRP) is a concentration of platelets in a small plasma volume, derived from the patient's blood. This autologous preparation is noted for its high platelet concentration, crucial for releasing growth factors vital for wound healing and tissue regeneration [9]. PRP enhances natural healing by promoting cellular migration and tissue repair across various clinical contexts [18].

The therapeutic principles of PRP therapy are based on its biological composition, where activated platelets release growth factors such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-), and vascular endothelial growth factor (VEGF). These factors, along with cytokines and extracellular matrix modulators, significantly influence biological processes including inflammation modulation, angiogenesis, and cellular proliferation essential for tissue healing [19, 20]. PRP's role in regenerative medicine is underscored by its categorization into biological, surgical, and advanced cell-based therapies, highlighting the potential of allogeneic approaches [12]. This categorization illustrates the evolving landscape of regenerative medicine, positioning PRP as a promising biological therapy with minimal invasiveness and enhanced healing outcomes in conditions like stress urinary incontinence.

3.3 Regenerative Medicine and PRP's Role

Regenerative medicine focuses on repairing and regenerating damaged tissues and organs, often utilizing the body's healing capabilities. PRP therapy has emerged as a key component of this field, enhancing tissue repair through concentrated growth factors from autologous blood [9]. Growth factors released by activated platelets, such as PDGF, TGF-, and VEGF, are vital for modulating inflammation, promoting angiogenesis, and stimulating cell proliferation involved in tissue repair [18].

PRP's application in regenerative medicine spans various clinical conditions, including musculoskeletal injuries and chronic wounds, and is increasingly explored for urological disorders like SUI. In SUI, PRP therapy aims to regenerate pelvic floor tissues and improve urethral sphincter function, addressing underlying pathophysiological mechanisms [15]. The autologous nature of PRP reduces risks of immune reactions and disease transmission, making it a safe therapeutic alternative.

The integration of PRP into regenerative medicine aligns with the trend towards personalized medicine, tailoring treatments to individual biological profiles. Ongoing research into the molecular pathways influenced by PRP holds promise for refining its use in regenerative therapies, optimizing outcomes for patients with SUI [12]. Establishing standardized protocols and validating the efficacy and safety of PRP in various applications are critical for advancing its clinical use.

3.4 Urology and Its Connection to SUI and PRP

Urology, which focuses on the urinary tract and male reproductive organs, plays a crucial role in managing SUI. This prevalent condition significantly impacts patients' quality of life, necessitating effective diagnosis and treatment strategies. Urologists are at the forefront of investigating innovative therapies, including PRP, which shows potential as a regenerative treatment for SUI. PRP therapy utilizes high concentrations of bioactive proteins from a patient's blood, promoting tissue healing and regeneration. Recent studies emphasize PRP's mechanisms in reducing inflammation and enhancing angiogenesis, crucial for tissue repair. However, variability in PRP preparation and the absence of standardized protocols challenge the translation of research outcomes into consistent clinical results. Continued exploration of PRP formulation and application in urology could enhance treatment options for SUI patients [12, 18, 15].

PRP therapy, involving autologous platelet concentrate injections, aims to improve tissue regeneration and urethral sphincter function in SUI patients. This approach leverages growth factors and bioactive proteins in PRP to modulate wound healing processes. Despite its promise, further research is needed to standardize preparation techniques and evaluate efficacy through large-scale clinical trials [12, 18, 19, 15, 20]. The integration of PRP into urological practice reflects a growing interest in regenerative medicine as a minimally invasive alternative to traditional surgical interventions, particularly relevant for patients seeking less invasive options.

The connection between urology, SUI, and PRP therapy is reinforced by ongoing research to establish standardized protocols and evaluate PRP's efficacy in clinical settings. Urologists are essential in conducting clinical trials that will determine PRP's viability as a mainstream SUI treatment. Addressing the incidence of de novo SUI post-pelvic organ prolapse surgery, as highlighted in benchmarks for post-surgical outcomes, represents an active area of investigation within urology

[2]. This emphasizes the importance of comprehensive urological care, incorporating preventive and therapeutic strategies for SUI, and leveraging advancements in regenerative medicine to improve patient outcomes.

4 Mechanism of Platelet-Rich Plasma Therapy

4.1 Role of Growth Factors and Platelet Activation

The efficacy of platelet-rich plasma (PRP) therapy is intrinsically linked to platelet activation and the release of pivotal growth factors necessary for tissue repair and regeneration. Agents such as chitosan can enhance this activation, thereby promoting wound healing [9]. Notable growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-), and vascular endothelial growth factor (VEGF), are crucial for cellular proliferation, angiogenesis, and inflammation modulation.

The interaction between these growth factors and the local tissue environment is intricate, affecting fluid pressures and mechanical properties, particularly in stress urinary incontinence (SUI) [5]. This underscores PRP's potential to address SUI's pathophysiological mechanisms by enhancing the structural integrity and function of affected tissues. Figure 4 outlines the key components and challenges of PRP therapy in addressing SUI, highlighting the role of growth factors, patient variability, and advanced techniques like CEPRP and FEM-FSI.

Variability in patient responses to PRP necessitates personalized treatment strategies [13]. The diverse female urinary microbiota (FUM) and its link to SUI symptoms and hormonal status further highlight the need for individualized PRP interventions [6]. As research progresses, refining platelet activation techniques and strategic growth factor deployment will be essential for optimizing PRP's therapeutic impact on SUI.



Figure 4: This figure outlines the key components and challenges of PRP therapy in addressing SUI, highlighting the role of growth factors, patient variability, and advanced techniques like CEPRP and FEM-FSI.

4.2 Biochemical Pathways in PRP Therapy

PRP therapy functions through complex biochemical pathways that promote wound healing and tissue regeneration, involving hemostasis, inflammation, and tissue remodeling [19]. Upon administration, PRP facilitates platelet aggregation and clot formation, creating a scaffold for cellular migration and repair.

During the inflammatory phase, platelet activation releases growth factors and cytokines that recruit immune cells, promoting angiogenesis, fibroblast activation, and tissue repair [19, 15, 21, 20, 22]. This coordinated response is crucial for debris clearance and infection prevention, fostering an environment conducive to tissue regeneration.

In the tissue remodeling phase, growth factors such as PDGF and TGF- stimulate fibroblast proliferation and differentiation, enhancing extracellular matrix synthesis and tissue architecture restoration. PRP's autologous nature, rich in these growth factors, positions it as a promising regenerative approach for various clinical conditions related to wound healing [18, 19, 15, 20, 22].

In SUI management, PRP may affect biochemical pathways regulating urethral pressure and pelvic floor integrity. The use of artificial neural networks (ANNs) to model urethral pressure dynamics based on age and position underscores PRP's potential to modulate these interactions and improve continence [3]. Understanding these pathways is vital for optimizing PRP therapy in clinical settings, particularly for SUI.

4.3 Classification and Standardization of PRP

Benchmark	Size	Domain	Task Format	Metric
SUI-TY[1]	4,004	Epidemiology	Survey Analysis	Prevalence Rate, Risk Factor Analysis
SUI-App[17]	61	Pelvic Health	Treatment Outcome Analysis	Patient Global Impression of Improvement, Odds Ratio
Trialstreamer[23]	160	Clinical Trials	Evidence Extraction	Recall, Precision
SUI-MB[14]	92,246	Urology	Complication Rate Analysis	Complication rate, Readmission rate

Table 1: This table provides a comprehensive overview of representative benchmarks used in various domains, including epidemiology, pelvic health, clinical trials, and urology. It details the size, domain, task format, and metrics employed for each benchmark, highlighting their specific applications and evaluation criteria. Such benchmarks are critical for assessing methodologies and ensuring robust analysis across different health-related studies.

The classification and standardization of PRP preparations are crucial for ensuring consistent therapeutic outcomes and facilitating comparative research. Various systems categorize PRP based on components like leukocyte content and fibrin architecture. A notable framework differentiates pure platelet-rich plasma (P-PRP), leucocyte- and platelet-rich plasma (L-PRP), pure platelet-rich fibrin (P-PRF), and leucocyte and platelet-rich fibrin (L-PRF), emphasizing differences in leukocyte and fibrin content [22]. Table 1 presents a detailed examination of key benchmarks utilized in the classification and standardization of PRP preparations, underscoring their significance in enhancing study comparability and clinical decision-making.

The development of these classification systems reflects the growing recognition of the need for standardization to enhance study comparability [24]. Frameworks considering platelet concentration, leukocyte presence, and preparation methods further highlight PRP formulations' complexity and the necessity for standardized protocols [15].

Introducing classification systems based on leukocyte content and fibrin architecture provides a structured approach to understanding PRP preparation variability [25]. These systems aid in characterizing PRP products and inform clinical decision-making by aligning specific formulations with therapeutic applications. As PRP research advances, establishing universally accepted standards will be critical for optimizing clinical efficacy and integrating PRP into mainstream therapeutic practices.

5 Clinical Trials and Evidence

5.1 Current Clinical Trials and Research Gaps

Research into platelet-rich plasma (PRP) therapy for stress urinary incontinence (SUI) is expanding, yet significant research gaps hinder its clinical adoption. Current trials explore PRP's regenerative capabilities, but challenges persist due to non-standardized preparation methods and the lack of large-scale randomized controlled trials [15]. This inconsistency complicates conclusions on efficacy and safety, underscoring the necessity for detailed protocols and consensus on optimal formulations [15].

A structured framework for clinical trial outcome mapping is essential for effective evidence retrieval and intervention comparison, crucial for informed healthcare decisions [23]. Future research should focus on larger randomized controlled trials to validate existing findings and explore new PRP applications in gynecology, emphasizing optimal preparation methods and dosages [16]. Standardized measurement protocols are vital for tracking SUI progression and risk factors, informing more effective interventions [7].

Retrospective analyses of medical records from women undergoing pelvic organ prolapse (POP) surgery reveal the incidence of de novo SUI postoperatively, highlighting the need for comprehensive urological care and PRP's potential role in addressing these issues [2]. Investigating long-term outcomes and patient-reported experiences with various surgical techniques and emerging technologies is critical for refining SUI treatment strategies [13].

Longitudinal studies on the female urinary microbiota (FUM) and its interactions with SUI and PRP therapy could enhance personalized treatment approaches and improve therapeutic outcomes [7]. Integrating these biological and clinical variables into future research is pivotal for establishing PRP as a reliable treatment option for SUI, ultimately enhancing patient care and quality of life.

As illustrated in Figure 5, the current challenges, future research directions, and potential applications of PRP in treating SUI highlight the pressing need for standardized protocols and larger trials. This visual representation reinforces the critical gaps in knowledge and the imperative for a concerted effort in research to advance the field.



Figure 5: This figure illustrates the current challenges, future research directions, and potential applications of platelet-rich plasma (PRP) in treating stress urinary incontinence (SUI), highlighting the need for standardized protocols and larger trials.

5.2 Efficacy and Outcomes of PRP Therapy

Emerging evidence supports the efficacy of platelet-rich plasma (PRP) therapy for stress urinary incontinence (SUI), owing to its natural treatment properties and minimal side effects, leading to significant improvements across various medical conditions [18]. In SUI, PRP therapy has shown promise in enhancing tissue regeneration and continence mechanisms.

Studies demonstrate that combining chitosan with specific molecular characteristics significantly boosts platelet activation and growth factor release, enhancing PRP therapy effectiveness [9]. Computational models, such as finite element method-fluid structure interaction (FEM-FSI), replicate clinical findings related to SUI, aiding in understanding bladder dynamics and PRP's impact [5].

Clinical trials report substantial patient outcome improvements following PRP therapy, with 56

Despite these promising results, interpreting PRP's efficacy is complicated by variability in preparation methods and patient-specific factors. The need for standardized protocols is evident, as inconsistencies in PRP formulations can lead to diverse clinical outcomes. Tools like Trialstreamer can enhance evidence synthesis from clinical trials, providing valuable insights for healthcare providers and researchers [23].

While PRP therapy offers a viable treatment option for SUI, further research is required to establish standardized preparation protocols and validate its long-term efficacy and safety. Addressing challenges related to inconsistent reporting of PRP protocols and variability in formulations is essential for optimizing PRP therapy, enhancing its efficacy, and broadening its clinical applications across medical specialties, particularly in regenerative medicine for musculoskeletal disorders, wound healing, and aesthetic procedures [21, 18, 15].

AI-generated, for reference only.

5.3 Comparative Frameworks and Novel Approaches

Advancing the clinical application of platelet-rich plasma (PRP) therapy, particularly for stress urinary incontinence (SUI), requires exploring comparative frameworks and novel approaches. These frameworks provide structured methodologies for evaluating the efficacy of various PRP formulations against established treatment modalities. Comprehensive frameworks are vital for identifying the most effective PRP protocols across medical specialties, thereby enhancing PRP therapy integration into standard clinical practice and addressing inconsistencies in protocol reporting and outcomes observed in current studies [21, 18, 15].

Computational models, such as finite element method-fluid structure interaction (FEM-FSI), simulate mechanical interactions within the bladder and urethra during stress events [5]. These models provide insights into the biomechanical effects of PRP therapy, informing the development of optimized treatment protocols tailored to individual patient needs.

Categorizing PRP into distinct formulations based on leukocyte content and fibrin architecture, such as pure platelet-rich plasma (P-PRP) and leucocyte- and platelet-rich plasma (L-PRP), creates a framework for comparative analysis [25]. This classification aligns specific PRP preparations with intended therapeutic applications, enhancing treatment strategy precision.

Integrating advanced technologies like artificial neural networks (ANNs) offers a novel approach for predicting treatment outcomes based on patient-specific variables, including age and urethral position [3]. ANNs can model complex interactions within the urinary system, serving as predictive tools for assessing PRP therapy's potential success in individual patients.

The incorporation of evidence retrieval tools, such as Trialstreamer, facilitates the synthesis and comparison of clinical trial data, enabling efficient evaluation of different PRP interventions [23]. This comparative analysis is crucial for identifying promising PRP approaches and guiding future research efforts.

Advancing comparative frameworks and investigating innovative methodologies in PRP therapy research are essential for enhancing its effectiveness in treating SUI. Given the variability in PRP preparation and application across medical specialties, optimizing these frameworks can lead to more standardized treatment approaches, improving clinical outcomes and addressing unmet needs in regenerative medicine for conditions like SUI [21, 18, 15, 12]. These efforts will contribute to establishing standardized protocols, improving patient outcomes, and expanding PRP's therapeutic potential in regenerative medicine.

6 Challenges and Considerations

6.1 Ethical and Regulatory Considerations

Implementing platelet-rich plasma (PRP) therapy for stress urinary incontinence (SUI) requires careful ethical and regulatory scrutiny to ensure both patient safety and treatment effectiveness. The autologous nature of PRP, derived from the patient's blood, minimizes risks of immune reactions and disease transmission, offering a favorable safety profile [9]. However, variability in preparation methods and lack of standardized protocols pose challenges to achieving consistent therapeutic outcomes [15]. Ethically, adherence to informed consent is crucial, with patients needing clear information on potential benefits, risks, and uncertainties, especially given PRP's experimental status in SUI [16]. Patients should be informed about the investigational nature of PRP therapy and the variability in outcomes due to individual factors and preparation techniques [18].

Regulatory oversight involves adhering to guidelines from health authorities that govern the preparation and application of biologic products. While PRP is often classified as a minimally manipulated autologous product, potentially exempting it from stringent regulations, this can lead to practice inconsistencies [15]. Establishing clear regulatory guidelines is essential to ensure PRP preparations meet quality and safety standards, safeguarding patient welfare and fostering confidence in clinical use. Ethical considerations also extend to equitable access to PRP therapy, addressing potential disparities in healthcare access due to cost and availability, particularly for conditions like SUI that significantly impact quality of life [1].

6.2 Limitations in Current Research

The research landscape for PRP therapy in SUI treatment is constrained by several limitations that hinder the establishment of standardized protocols and validation of clinical efficacy. A significant challenge is the heterogeneity of PRP products and the lack of consensus on preparation methods, resulting in inconsistent therapeutic outcomes and complicating clinical translation [15]. Variability in PRP formulations leads to differing concentrations of platelets and growth factors, complicating definitive conclusions on treatment effectiveness [16]. Additionally, the predominance of small sample sizes and the absence of large-scale randomized controlled trials limit the robustness and generalizability of findings across diverse populations [16]. The reliance on retrospective designs without a priori power calculations further limits result generalizability and introduces biases [2]. High selection bias and non-standardized methodologies exacerbate these issues, highlighting the need for more rigorous research designs [7].

Self-reported data and cross-sectional study designs also present limitations, as they do not adequately capture the long-term efficacy and safety of PRP therapy [7]. The lack of comprehensive studies on psychological and lifestyle factors integral to understanding SUI's full impact further constrains current research [4]. Moreover, variability in study designs and insufficient long-term data for newer techniques complicate direct comparisons and hinder the establishment of evidence-based treatment guidelines. Challenges in achieving high precision in evidence extraction, particularly with complex trial data, further complicate the synthesis of findings and the development of effective clinical protocols [23]. Addressing these limitations necessitates large-scale randomized controlled trials with standardized protocols to ensure consistent PRP preparation and application, crucial for advancing the understanding of PRP therapy's mechanisms and optimizing its clinical efficacy for SUI management.

6.3 Emerging Therapies and Challenges

The therapeutic landscape for stress urinary incontinence (SUI) is evolving, with emerging treatments such as PRP therapy at the forefront of innovative approaches. PRP therapy leverages the regenerative potential of autologous growth factors to enhance tissue repair and improve urinary continence mechanisms. However, its clinical integration faces challenges, including variability in PRP preparation methods, inconsistent protocol reporting across studies, and difficulties in translating preclinical findings to human applications. Addressing these issues is crucial for maximizing PRP's therapeutic capabilities for conditions like musculoskeletal disorders, osteoarthritis, and chronic wounds [21, 24, 15]. A primary challenge is the lack of standardized preparation protocols, leading to variability in platelet concentration and growth factor composition across formulations [15]. This inconsistency complicates the evaluation of PRP's efficacy and hinders the development of universally accepted treatment guidelines. Furthermore, the absence of large-scale randomized controlled trials limits the ability to draw definitive conclusions about PRP's long-term effectiveness and safety in SUI management [16].

Emerging therapies for SUI also encompass advanced cell-based approaches and tissue engineering techniques aimed at restoring pelvic floor function through tissue regeneration. While promising, these interventions face similar challenges related to standardization, regulatory approval, and the necessity for robust clinical evidence [12]. Successfully integrating such therapies into clinical practice requires a comprehensive understanding of their mechanisms and the development of protocols ensuring consistent and reproducible outcomes. Additionally, exploring combination therapies, where PRP is used alongside other regenerative modalities, presents opportunities to enhance treatment efficacy. However, these approaches necessitate careful consideration of potential interactions between therapeutic agents and the optimization of treatment regimens to maximize patient benefits [18].

The challenges associated with PRP and other emerging therapies underscore the importance of interdisciplinary collaboration in advancing regenerative medicine for SUI. Researchers, clinicians, and regulatory bodies must unite to establish standardized protocols, conduct rigorous clinical trials, and ensure accessible innovative treatments for patients in need. Effectively addressing the multifaceted challenges of PRP therapy and other emerging treatments is essential for unlocking their full potential in managing SUI, particularly with respect to patient expectations, pelvic floor muscle strength, and lifestyle factors as highlighted by recent studies [17, 3, 26, 15, 8].

AI-generated, for reference only.

7 Future Directions

Exploring future directions for platelet-rich plasma (PRP) therapy involves addressing key areas to enhance its application and understanding. Standardizing PRP preparation protocols is critical for achieving consistent therapeutic outcomes, improving reliability, and enhancing effectiveness across clinical settings.

7.1 Standardization of PRP Preparation Protocols

Standardizing PRP preparation is vital for consistent therapeutic outcomes and clinical integration. Current variability in PRP formulations, due to differences in platelet concentration, leukocyte content, and growth factors, complicates efficacy and safety evaluations [15]. Developing standardized techniques and reporting guidelines will enhance evidence quality and study comparability [21]. Future research should explore leukocyte roles in PRP to optimize formulations for specific indications [15]. Large-scale trials are needed to validate these methods, using objective measures and larger samples for robustness [19, 8]. Exploring PRP's synergy with other regenerative therapies could enhance treatment efficacy [18]. Addressing PRP variability is crucial for optimizing its clinical applicability and patient outcomes [21, 15].

7.2 Large-scale Randomized Controlled Trials

Large-scale randomized controlled trials (RCTs) are essential to establish PRP's efficacy and safety for stress urinary incontinence (SUI) [16]. These trials should standardize PRP preparation and treatment administration to reduce outcome variability [15]. Comprehensive outcome measures, including clinical and patient-reported outcomes, must capture PRP's effects on urinary continence and quality of life [8]. Diverse patient populations will enhance generalizability and inform personalized treatment strategies [7]. Long-term safety and efficacy, along with potential adverse effects, should be investigated [13]. Advanced technologies like artificial neural networks (ANNs) can optimize treatment protocols based on individual profiles [3]. Well-designed RCTs will build a robust evidence base to support PRP's adoption in SUI treatment, enhancing patient care.

7.3 Exploration of Biological Mechanisms

Understanding PRP's biological mechanisms is crucial for optimizing its therapeutic efficacy. Research should identify specific PRP components contributing to therapeutic effects, facilitating targeted therapies [21]. Computational modeling advancements, such as fluid-structure interaction (FSI) techniques, are essential for simulating conditions relevant to PRP therapy [5]. MRI data can enhance simulation accuracy, providing insights into PRP's biomechanical interactions in tissues. Integrating chitosan with PRP shows promise in enhancing platelet activation, suggesting further investigation areas [9]. Prospective studies on surgical techniques and urinary continence can inform PRP therapies for postoperative complications [2]. Improved data extraction and expanded datasets will enhance PRP outcome evaluations, advancing understanding of its biological mechanisms [23].

7.4 Longitudinal Studies and Long-term Outcomes

Longitudinal studies are pivotal for understanding PRP's long-term efficacy and safety in SUI. These designs track SUI progression and PRP's sustained effects, offering insights across specialties like musculoskeletal injuries and chronic wound management [21, 15]. Investigating the female urinary microbiota (FUM) and hormonal status in urinary incontinence symptoms can lead to personalized treatment strategies [6]. Long-term outcome assessments should monitor urinary continence improvements, quality of life, and psychological well-being. Comprehensive evaluations are crucial for understanding PRP's long-term effects and detecting delayed adverse effects. Consistent reporting and characterization of PRP formulations are necessary for efficacy and safety assessments [21, 18]. Longitudinal studies also compare PRP's long-term efficacy with other treatments, leveraging data extraction methods for high-quality evidence [26, 21, 23, 15]. Implementing these studies is vital for enhancing PRP's long-term outcomes, particularly in SUI management [12, 15, 21, 24, 22].

7.5 Integration with Emerging Technologies

Integrating emerging technologies with PRP research can enhance treatment efficacy and precision for SUI. Computational models, like finite element method-fluid structure interaction (FEM-FSI) and artificial neural networks (ANNs), simulate urinary system dynamics, improving understanding of conditions like SUI [3, 5, 26]. These models aid in developing personalized treatment protocols, optimizing PRP application. Machine learning and data analytics can analyze clinical trial data, identifying factors influencing PRP efficacy [23]. Advanced imaging techniques, such as MRI, refine computational models, assessing PRP's impact on tissue regeneration [5]. Exploring biomaterials like chitosan with PRP therapy can enhance regenerative potential [9]. Interdisciplinary collaboration is crucial for advancing PRP research and clinical applications. Integrating emerging technologies will transform SUI treatment, facilitating precise and personalized interventions, addressing unmet needs for effective strategies [21, 15, 12].

8 Conclusion

The survey elucidates the complex etiology of stress urinary incontinence (SUI), emphasizing the interplay between bladder neck and urethral dysfunction, which necessitates the adoption of standardized diagnostic methodologies to enhance clinical understanding. Traditional management techniques, such as mid-urethral slings, remain the cornerstone of surgical intervention; however, there is a compelling demand for exploration into innovative treatments and preventive strategies. Tailoring therapeutic approaches to align with individual patient profiles and preferences is crucial, with informed consent processes ensuring a comprehensive understanding of potential risks and benefits associated with both surgical and non-surgical options.

Platelet-rich plasma (PRP) therapy represents a promising non-surgical treatment for SUI, characterized by its minimal adverse effects and its potential for tissue regeneration. Nevertheless, extensive research is required to substantiate its effectiveness and establish its position in the management of gynecological conditions. Progress in this field hinges on the implementation of standardized protocols and the integration of personalized medicine, which are vital for optimizing PRP therapy, enhancing patient outcomes, and expanding the array of therapeutic possibilities for SUI.

AI-generated, for reference only.

References

[1] Rui Qin Zhang, Man Cheng Xia, Fan Cui, Jia Wei Chen, Xiao Dong Bian, Hong Jie Xie, and Wei Bing Shuang. Epidemiological survey of adult female stress urinary incontinence. *BMC women's health*, 21:1–10, 2021.

[2] Alexandriah N Alas, Orawee Chinthakanan, Luis Espaillat, Leon Plowright, G Willy Davila, and Vivian C Aguilar. De novo stress urinary incontinence after pelvic organ prolapse surgery in women without occult incontinence. *International urogynecology journal*, 28:583–590, 2017.

[3] Mojtaba Barzegari, Bahman Vahidi, Mohammad Reza Safarinejad, and Marzieh Hashemipour. Pathological analysis of stress urinary incontinence in females using artificial neural networks, 2018.

[4] Xunguo Yang, Xingqi Wang, Zhenhua Gao, Ling Li, Han Lin, Haifeng Wang, Hang Zhou, Daoming Tian, Quan Zhang, and Jihong Shen. The anatomical pathogenesis of stress urinary incontinence in women. *Medicina*, 59(1):5, 2022.

[5] Mojtaba Barzegari, Bahman Vahidi, and Mohammad Reza Safarinejad. A clinical and finite elements study of stress urinary incontinence in women using fluid-structure interactions, 2017.

[6] Krystal J Thomas-White, Stephanie Kliethermes, Leslie Rickey, Emily S Lukacz, Holly E Richter, Pamela Moalli, Philippe Zimmern, Peggy Norton, John W Kusek, Alan J Wolfe, et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. *American journal of obstetrics and gynecology*, 216(1):55–e1, 2017.

[7] Kobra Falah-Hassani, Joanna Reeves, Rahman Shiri, Duane Hickling, and Linda McLean. The pathophysiology of stress urinary incontinence: a systematic review and meta-analysis. *International Urogynecology Journal*, 32:501–552, 2021.

[8] José Alberto Benítez-Andrades, María Teresa García-Ordás, María Álvarez González, Raquel Leirós-Rodríguez, and Ana F López Rodríguez. Detection of the most influential variables for preventing postpartum urinary incontinence using machine learning techniques, 2024.

[9] Hidemi Hattori and Masayuki Ishihara. Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. *Experimental and Therapeutic Medicine*, 13(3):1176–1180, 2017.

[10] Emily S Lukacz, Yahir Santiago-Lastra, Michael E Albo, and Linda Brubaker. Urinary incontinence in women: a review. *Jama*, 318(16):1592–1604, 2017.

[11] Giampiero Capobianco, Massimo Madonia, Sonia Morelli, Francesco Dessole, Davide De Vita, Pier Luigi Cherchi, and Salvatore Dessole. Management of female stress urinary incontinence: a care pathway and update. *Maturitas*, 109:32–38, 2018.

[12] Maddalena Mastrogiacomo, Marta Nardini, Maria Chiara Collina, Cristiana Di Campli, Gilberto Filaci, Ranieri Cancedda, and Teresa Odorisio. Innovative cell and platelet rich plasma therapies for diabetic foot ulcer treatment: the allogeneic approach. *Frontiers in bioengineering and biotechnology*, 10:869408, 2022.

[13] Kathleen C Kobashi, Michael E Albo, Roger R Dmochowski, David A Ginsberg, Howard B Goldman, Alexander Gomelsky, Stephen R Kraus, Jaspreet S Sandhu, Tracy Shepler, Jonathan R Treadwell, et al. Surgical treatment of female stress urinary incontinence: Aua/sufu guideline. *The Journal of urology*, 198(4):875–883, 2017.

[14] Kim Keltie, Sohier Elneil, Ashwani Monga, Hannah Patrick, John Powell, Bruce Campbell, and Andrew J Sims. Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women. *Scientific reports*, 7(1):12015, 2017.

[15] Peter Everts, Kentaro Onishi, Prathap Jayaram, José Fábio Lana, and Kenneth Mautner. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. *International journal of molecular sciences*, 21(20):7794, 2020.

[16] Ayman Shehata Dawood and Hesham Abdelaziz Salem. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. *Clinical and experimental reproductive medicine*, 45(2):67, 2018.

[17] Emma Nyström, Ina Asklund, Malin Sjöström, Hans Stenlund, and Eva Samuelsson. Treatment of stress urinary incontinence with a mobile app: factors associated with success. *International urogynecology journal*, 29:1325–1333, 2018.

[18] Pouria Samadi, Mohsen Sheykhhasan, and Hamed Manoochehri Khoshinani. The use of platelet-rich plasma in aesthetic and regenerative medicine: a comprehensive review. *Aesthetic plastic surgery*, 43:803–814, 2019.

[19] Ranjan Verma, Subodh Kumar, Piyush Garg, and Yogesh Kumar Verma. Platelet-rich plasma: a comparative and economical therapy for wound healing and tissue regeneration. *Cell and Tissue Banking*, 24(2):285–306, 2023.

[20] Julia Etulain. Platelets in wound healing and regenerative medicine. *Platelets*, 29(6):556–568, 2018.

[21] Jaron Nazaroff, Sarah Oyadomari, Nolan Brown, and Dean Wang. Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of level i and ii studies. *PLoS One*, 16(4):e0250007, 2021.

[22] Adriana Bos-Mikich, Ricardo de Oliveira, and Nilo Frantz. Platelet-rich plasma therapy and reproductive medicine. *Journal of assisted reproduction and genetics*, 35(5):753–756, 2018.

[23] Benjamin E. Nye, Ani Nenkova, Iain J. Marshall, and Byron C. Wallace. Trialstreamer: Mapping and browsing medical evidence in real-time, 2020.

[24] Thomas Collins, Dinesh Alexander, and Bilal Barkatali. Platelet-rich plasma: a narrative review. *EFORT Open Reviews*, 6(4):225–235, 2021.

[25] Rubina Alves and Ramon Grimalt. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. *Skin appendage disorders*, 4(1):18–24, 2018.

[26] Gabriela Gonzalez, Kristina Vaculik, Carine Khalil, Yuliya Zektser, Corey Arnold, Christopher V Almario, Brennan MR Spiegel, and Jennifer T Anger. Women's experience with stress urinary incontinence: insights from social media analytics. *The Journal of urology*, 203(5):962–968, 2020.